share_log

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Benzinga ·  Sep 3 19:32  · Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment